B-Cell Receptor Signaling Regulation and Aggressive B-Cell Lymphomas: History
View Latest Version
Please note this is an old version of this entry, which may differ significantly from the current revision.
Subjects: Cell Biology | Oncology
Contributor:
Juliana Santos
,
Gael Roue

The proliferation and survival signals emanating from the B-cell receptor (BCR) constitute a crucial aspect of mature lymphocyte’s life. Dysregulated BCR signaling is considered a potent contributor to tumor survival in different subtypes of B-cell non-Hodgkin lymphomas (B-NHLs). The emergence of BCR-associated kinases as rational therapeutic targets has led to the development and approval of several small molecule inhibitors targeting either Bruton’s tyrosine kinase (BTK), spleen tyrosine kinase (SYK), or phosphatidylinositol 3 kinase (PI3K), offering alternative treatment options to standard chemoimmunotherapy, and making some of these drugs valuable assets in the anti-lymphoma armamentarium. Despite their initial effectiveness, these precision medicine strategies are limited by primary resistance in aggressive B-cell lymphoma such as diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL), especially in the case of first generation BTK inhibitors. In these patients, BCR-targeting drugs often fail to produce durable responses, and nearly all cases eventually progress with a dismal outcome, due to secondary resistance. 

  • B-cell non-Hodgkin lymphoma (B-NHL)
  • B-cell receptor (BCR)
  • acalabrutinib
  • combination therapies

1. Introduction

The introduction of massive sequencing approaches together with the development of more physiological preclinical models, has recently allowed a deeper understanding of the relevance of B-cell signaling pathways in the molecular pathogenesis of B-cell non-Hodgkin lymphoma (B-NHL). These advances provided significant insights into the differential response to standard immunotherapeutic regimens across the most aggressive B-NHL subtypes, including diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL), and yielded several promising targets for novel antitumor therapies for these life-threatening diseases. As a result, in the last two decades the treatment landscape of MCL, and to a lesser extent, DLBCL, has expanded from conventional cytotoxic chemotherapies to encompass targeted small-molecule drugs, monoclonal antibodies, antibody-drug conjugates, and cellular therapies. Among these new approaches, a significant proportion of MCLs and DLBCLs have been shown to be addicted to B-cell receptor (BCR) signaling, and/or to its downstream oncogenic pathways such as nuclear factor–κB (NF-κB) and phosphatidylinositol 3-kinase (PI3K). Based on these observations, various specific inhibitors targeting these signaling cascades have been developed and evaluated in the clinics, essentially in patients with relapsed and/or refractory (R/R) disease.

2. Pharmacological Targeting of BCR Upstream Kinases and Its Limitations in MCL and DLBCL

2.1. Preclinical Drug Development

Studies targeting Bruton’s tyrosine kinase (BTK) have attracted substantial attention due to its crucial role in the BCR pathway and BTK inhibitors (BTKi) have shown promising antitumor activities, both in vivo and in vitro models. According to its mechanism of action and their binding affinity and activity, the BTKi are classified into two types: irreversible inhibitors, where they bind to the amino acid residue Cys481 forming a covalent bond; or the reversible inhibitors, which bind to an inactive conformation of the kinase, by accessing the specific SH3 pocket of BTK [1].
The majority of BTKi are irreversible inhibitors, from which the first-generation inhibitor is ibrutinib. In 2010, ibrutinib was demonstrated to have selective toxicity in DLBCL cell lines with chronically active BCR signaling with sub-nanomolar activity (IC50 = 0.5 nM), by preventing the BTK autophosphorylation [2] and in vivo data confirmed its potential [3]. Ibrutinib, when combined with bortezomib, also presented a synergism by enhancing apoptosis in DLBCL and MCL cells through AKT and NFκB inactivation [4], while in DLBCL it showed cumulative antitumor effects with other agents, such as enzastaurin [5] or lenalidomide [6]. Together these preclinical studies provided detailed insights into the mechanism of action for the subsequent clinical trials (described below).
The off-target side effects of ibrutinib have led to the development of second-generation inhibitors of which acalabrutinib demonstrated to have less off-target kinases inhibition [7] and also to be more potent in in vitro assays and in vivo canine models of DLBCL and xenograft models derived from activated B-cell-like (ABC)-DLBCL and MCL [7][8][9]. Another more selective inhibitor is zanubrutinib, which also showed antitumor activity in the nanomolar range in MCL cell lines as well as in ABC-DLBCL cells, with a similar effect as ibrutinib but with less off-target effects and prolonged overall survival in a DLBCL xenograft model [10][11]. Alternative irreversible BTKi are M2951 and M7583, presenting an in vivo antitumor activity in preclinical models of ABC-DLBCL [12]; spebrutinib (CC-292), with high efficacy as a single agent as well as in synergistic combinations in ABC-DLBCL, but limited efficacy in GCB-DLBCL [13]; tirabrutinib (ONO/GS-4059), which is showing promising results in preclinical studies [14][15]; TG-1701, a more selective inhibitor, presenting Ikaros as an important biomarker for response and efficacy, both in vitro and in vivo [16]; and other compounds, currently under development with promising results in vitro, such as QL47 [17].
However, primary and secondary resistances have emerged from the irreversible BTKi ibrutinib, resulting in a poorer prognosis of relapsed lymphoma patients. In DLBCL and MCL the mechanisms of resistance are not as well-known as in CLL, where the cause of resistance has been identified to be related in part to mutations at the covalent site (C481) on BTK and also phospholipase C-γ (PLCγ2), resulting in a downstream signal activation [18].
To overcome the irreversible BTKi limitations (off-target side effects and long-term toxicities), new reversible compounds are under development that will be helpful for the ibrutinib-resistant patients. Some of the most relevant reversible inhibitors are ARQ-531, which have demonstrated potent activity against both BTK wild-type and C481S mutant in ABC- and GCB-DLBCL cell lines [19][20]; LFM-A13, a dual inhibitor against BTK and PLK [21]; HBW-3-10, with great potency and pharmacokinetic profile and better results than the ibrutinib, when compared in xenograft models [22]; fenebrutinib, a potent reversible inhibitor against BTK C4815 mutant [23], CG-806, with great effects in MCL and DLBCL in vitro and MCL PDX mice models [24], CB1763, with a strong effect on C481S mutant BTK [25]; and Pirtobrutinib (LOXO-305), with potent antitumor effects both in vitro and in vivo [26][27].
Another interesting novel strategy to overcome ibrutinib resistance is the proteolysis-targeting chimera (PROTAC), which will selectively target BTK C481S mutant. L18I has been reported to inhibit proliferation in BTK mutant DLBCL cell lines and induce rapid tumor regression in C481S BTK HBL-1 xenograft tumors [28]. In addition, P13I and compound 6e, are under development in preclinical studies with promising results [29][30][31][32].
The next key component of the BCR signaling pathway, which has gained relevance as a therapeutic target, is SYK. R406 is a SYK inhibitor that induces apoptosis in the majority of DLBCL cell lines studied by the inhibition of both tonic and induced BCR signaling [33]; however, it also inhibits other kinases [34]. Its oral prodrug is R788, fostamatinib, which has shown great efficiency in B-NHL-like mice models and is currently in clinical trials (see below) [35][36]. Another SYK inhibitor is cerdulatinib, which has demonstrated great antitumor activity by inducing apoptosis and cell cycle arrest in both ABC- and GCB-DLBCL cell lines [37]. Similar results were being observed for PRT060318, where the cell cycle arrest effect by the inhibitor was mimicked by a genetic reduction of SYK using a siRNA [34]. Entospletinib (GS-9973) selectively inhibits SYK and presents a synergistic antitumor effect with vincristine, both in a panel of DLBCL cell lines and in a DLBCL tumor xenograft model [38]. TAK-659 is a dual SYK/FLT-3 inhibitor with antitumor activity in DLBCL cell line xenograft models and in patient-derived xenografts (PDX) [39][40]. ASN002 is a dual JAK/SYK inhibitor, showing a great antiproliferative activity in in vitro and in in vivo models. Moreover, it also showed antitumor activity in ibrutinib-resistant cell lines [41].
Lastly, elevated or aberrant activation of mTOR has been identified in several cell lines and patient samples of DLBCL and MCL; thus, its targeting is a therapeutic approach alone or in combination [42]. Rapamycin, or sirolimus, is an antibiotic and the first mTOR inhibitor discovered, from which novel rapamycin analogs have emerged: temsirolimus that has shown antitumor activity in MCL cell lines [43]; and everolimus (RAD001), showing an effect associated with cell-cycle arrest in MCL [44]. To achieve a more potent anticancer activity, small molecules that inhibit both mTORC1 and mTORC2 have been developed. Among them, CC-223 is a potent and selective inhibitor that shows a better induction in apoptosis, when compared to rapamycin in a panel of DLBCL, FL, and MCL cell lines [45]. AZD014 has been shown to synergize with ibrutinib and cause tumor regression in in vivo experiments in ABC-DLBCL [46]. Finally, PQR309 is a dual PI3K/mTOR inhibitor with promise for advancing into clinical trials, alone or in combination with other treatments [47]. Figure 1 summarizes the main BCR signaling therapeutic targets in DLBCL and MCL.
Figure 1. Regulation of BCR signaling and the therapeutic inhibition of BTK and PI3K in DLBCL and MCL. (Left panel) Antigen-dependent and chronic active BCR signaling; (Right panel) Tonic BCR signaling.

2.2. Clinical Experience with the Targeting of Apical BCR Kinases in DLBCL and MCL

The arrival of ibrutinib to the therapeutic armamentarium of MCL was a real breakthrough and has changed the treatment paradigm in the relapsed/refractory (R/R) setting. The first clinical results from the phase 2 pivotal study in heavily pre-treated MCL [48] led to an accelerated approval of ibrutinib for R/R MCL in 2013 by the U.S. Food and Drug Administration (FDA) and in 2014 by the European Medicines Agency (EMA). Ibrutinib showed an overall response (OR) and complete response (CR) rates of 68% and 21%, respectively, with a median duration of response (DOR) of 17.5 months, which were significantly higher than those observed with the previously approved targeted agents, bortezomib, temsirolimus, and lenalidomide, whose rates of OR and CR were 22–33% and 8–10%, respectively, with median DOR ranging between 8 months with bortezomib [49] and temsirolimus [50][51][52] and 16 months with lenalidomide [53][54]. The phase 3 RAY study demonstrated the superiority of ibrutinib versus temsirolimus also in terms of progression free survival (PFS) (15.6 vs. 6.2 months) [55]. In addition, patients receiving ibrutinib on their first relapse showed a significantly higher PFS than those treated with ibrutinib in later relapses (25.4 vs. 10.3 months, respectively), which was an unexpected finding, not observed in the temsirolimus arm, where the PFS was the same for all the patients regardless of the number of previous lines received. Another study pooling together the data from up to 330 patients with R/R MCL prospectively included in two phase 2 trials and in the phase 3 RAY study confirmed that the sooner ibrutinib is used when patients with MCL relapse after the first line, the better the results will be in terms of PFS, but also of CR rate (32% when ibrutinib was used after only one previous line versus 14% when used in later relapses), DOR (35.6 vs. 16.6 months with early vs. late use of ibrutinib) and overall survival (OS) (61.6 vs. 22.5 months) [56], leading to the current unanimous recommendation about the preferential use of ibrutinib as the first option in relapse, in order to get the most out of this active drug in R/R MCL.
Ibrutinib is a well-tolerated and safe drug, but the concern about its collateral effects on other kinases besides BTK, associated with a higher risk of bleeding (mostly grade 1–2 events in the clinical practice) and cardiovascular events (atrial fibrillation and hypertension) led to the development of new generation BTKi with reduced off-target effects. Acalabrutinib and zanubrutinib are the first two of this new generation BTKi with an improved safety profile [57][58] approved for patients with R/R MCL, with encouraging data on efficacy and survival confirming how this family of drugs has definitely changed the landscape of salvage treatment in MCL. Indeed, several newer, safer, and more potent BTKi are coming along, both covalent irreversible (such as acalabrutinib and zanubrutinib) and non-covalent reversible BTKi (such as pirtobrutinib and others), whose main clinical data are summarized in Table 1.
Table 1. Clinical trials with targeted BCR inhibition as single agent treatments.
Targets Drug/Regimen Clinical Trial Phase Nb Pts Status Conditions Response Data References
BTK Acalabrutinib NCT02112526 1 21 Active R/R DLBCL ORR 24%, CR 19%
AEs Grade 3/4 44%		 [59]
BTK DTRMWXHS-12 NCT02891590 1 13 Completed R/R B-cell Lymphomas Well-tolerated and no DLT achieved [60]
BTK Ibrutinib NCT00849654 1 66 Completed B-cell Lymphomas ORR 60%
CR 16%
PFS 13.6 months		 [61]
BTK Ibrutinib NCT01704963 1 15 Completed R/R B-cell Lymphomas ORR 73.3% [62]
BTK Ibrutinib NCT01325701 2 78 Completed R/R DLBCL CR or PR in 37% (ABC) and in 5% (GCB) [63]
BTK Ibrutinib NCT02207062 2 20 Active R/R B-cell Lymphomas ORR 35%
CR 15%
PFS 4.1 months
OS 22.8 months		 [64]
BTK Ibrutinib NCT01804686 3 700 Active CLL, SLL, MCL, FL DLBCL, WM CR 27.6%
PR 42.2%
PFS 12.5 months		 [65]
BTK TG1701 NCT03664297 1 86 Active B-cell Lymphomas NA NA
BTK Vecabrutinib NCT03037645 1 & 2 39 Terminated CLL, SLL, MCL, WM, DLBCL, FL, MZL Well tolerated but terminated due to insufficient evidence of activity NA
BTK Zanubrutinib NCT03189524 1 44 Completed R/R MCL CR 86.6%
DOR 19.5 months
PFS 22.1 months		 [58]
BTK Zanubrutinib NCT03145064 2 41 Completed DLBCL ORR 29.3%
CR 17.1%
DOR 4.5 months
PFS 2.8 months?		 [66]
mTOR Onatasertib NCT01177397 1 & 2 173 Completed MM, DLBCL Acceptable safety
PR 17.6%		 [67]
PI3K Acalisib NCT01705847 1 39 Completed B-cell Lymphomas ORR 28.6%
AEs grade > 3 55.3%		 [68]
PI3K AMG-319 NCT01300026 1 28 Completed CLL, DLBCL, MCL AEs grade > 3 25% [69]
PI3K Buparlisib NCT01693614 2 72 Completed DLBCL, MCL, FL ORR 11.5% in DLBCL and 22.7% in MCL [70]
PI3K Buparlisib NCT01719250 Early 1 7 Completed R/R DLBCL, R/R FL, R/R MCL NA NA
PI3K Fimepinostat NCT01742988 1 106 Completed R/R DLBCL CR 12.5%
PR 37.5%
SD 37.5%		 [71]
PI3K Idelalisib NCT03151057 1 60 Active CLL, FL, MCL, DLBCL NA NA
PI3K KA2237 NCT02679196 1 23 Completed B-cell Lymphomas ORR 37%
AEs grade > 3 43%		 [72]
PI3K Parsaclisib NCT03688152 1 9 Completed R/R DLBCL NA NA
PI3K Parsaclisib NCT03314922 1 17 Active B-cell Lymphomas NA NA
PI3K Parsaclisib NCT02998476 2 60 Completed R/R DLBCL ORR 25.5%
DOR 6.2 months		 [73]
PI3K Tenalisib NCT02017613 1 35 Completed B-cell Lymphomas ORR 19%
CR 6%
PR 13%		 [74]
PI3K Umbralisib NCT01767766 1 90 Completed NHL, CLL ORR 24%
CR 8%
PR 16%
AEs grade > 3 in less than 5%		 [75][76]
SYK Fostamatinib NCT00446095 1 & 2 81 Completed B-cell Lymphomas ORR 22% in DLBCL and 11% in MCL
PFS 4.2 months		 [77]
Abbreviations: FL, follicular lymphoma; DLBCL, diffuse large B-cell lymphoma; MCL, mantle cell lymphoma; MZL, marginal zone lymphoma; NHL, non-Hodgkin lymphoma; CLL, chronic lymphocytic leukemia; MM, multiple myeloma; WM, waldenstrom’s macroglobulinemia; ORR, overall response rate; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; DOR, duration of response; PFS, progression-free survival; OS, overall survival; AEs, adverse effects; NA, not available.
The clinical experience with PI3K inhibitors (PI3Ki) in MCL is far from that of BTKi and none of the PI3Ki tested in aggressive B-NHL (MCL or DLBCL), either δ-selective or pan-PI3Ki, has been approved to date, mainly due to an insufficient efficacy in monotherapy. One of the most recently evaluated PI3Ki in MCL and DLBCL, parsaclisib, a δ-selective PI3Ki with an improved toxicity profile, showed initial promising results in a phase 1/2 study [78], which unfortunately were not confirmed later on in the respective phase 2 studies. The CITADEL-205 study in R/R MCL showed activity of parsaclisib only in patients who had not received previous BTKi, with an objective response rate (ORR) and CR of 70% and 15.6%, respectively [79], but the results in the most realistic cohort, the BTKi-experienced patients, were disappointing, with ORR and CR of only 35.5% and 2.9%, respectively [80]. In R/R DLBCL, despite an initial ORR of 30% in the phase 1/2 study [78], the CITADEL-202 study was prematurely closed due to the high proportion of patients with disease progression during treatment: 95% (52 out of 55 patients) in the BTKi-naïve arm and 80% (4 out of 5 patients) in the BTKi-experienced arm [73]. These and other PI3Ki are currently undergoing evaluation in combination with chemotherapy and other targeted drugs (Table 2).
Table 2. Clinical trials with targeted BCR inhibition in combinatorial treatments.
Targets Drug/Regimen Clinical Trial Phase Nb Pts Status Conditions Response Data References
BTK
PD1		 Acalabrutinib + Pembrolizumab NCT02362035 1 & 2 161 Active R/R DLBCL ORR 26%
Discontinuation was due to PD (62%) and AEs (26%)		 [81]
BTK Acalabrutinib + R-CHOP NCT03571308 1 & 2 39 Active nHL NA NA
BTK Ibrutinib + R-CHOP NCT01855750 3 838 Completed B-cell Lymphomas ORR 93.6% [82]
BTK Ibrutinib + R-ICE NCT02219737 1 26 Completed DLBCL ORR 90% [83]
BTK Ibrutinib + CAR-T cell NCT05020392 3 24 Active DLBCL, MCL, CLL, SLL, BL ORR 83% [84]
BTK
PDL1
4-1BB
CD20		 Ibrutinib + Avelumab + Utomilumab + Rituximab NCT03440567 1 16 Active R/R DLBCL, R/R MCL, Transformed FL NA NA
BTK Ibrutinib + Immuno-chemotherapy NCT02055924 1 85 Terminated B-cell Lymphomas CR 42%
PR 25%
Terminated due to due to veno occlusive disease		 [85]
BTK JAK1 Ibrutinib + Itacitinib NCT02760485 1 & 2 33 Active B-cell Lymphomas ORR 24% [86]
BTK Ibrutinib + Lenalidomide NCT01955499 1 34 Active R/R DLBCL, R/R FL, R/R MZL, R/R MCL NA NA
BTK
CD20		 Ibrutinib + Rituximab NCT01980654 2 80 Completed B-cell Lymphomas ORR 85–75% [87]
BTK
CD20		 Ibrutinib + Rituximab + Bendamustine NCT01479842 1 48 Active MZL, FL, MCL, WM OR 94% in MCL and 37% in DLBCL CR 76% in MCL and 31% in DLBCL [88]
BTK Ibrutinib + Rituximab + Lenalidomide NCT02636322 2 60 Active DLBCL ORR 65%
DOR 15.9 months		 [89]
BTK
CD20		 Ibrutinib + Rituximab + Lenalidomide NCT02077166 1 & 2 134 Completed R/R DLBCL ORR 47%
CR 28%
PFS 21 months
AEs grade > 3 in less 30% patients		 [90]
BTK
CD20		 Ibrutinib + Rituximab + Venetoclax NCT03136497 1 10 Active R/R DLBCL NA NA
BTK Spebrutinib NCT01351935 1 113 Completed B-cell Lymphomas ORR 53% [91]
BTK Spebrutinib + Lenalidomide NCT01766583 1 18 Completed R/R B-cell Lymphomas NA NA
BTK
CD20		 Zanubrutinib + Rituximab NCT03520920 2 41 Completed MZL, FL, DLBCL ORR 35%
PFS 3.38 months		 [92]
BTK
mTOR		 DTRMWXHS-12 + Everolimus + Pomalidomide NCT02900716 1 48 Completed B-cell Lymphomas Well-tolerated and no DLT achieved [60]
BTK
PI3K		 Ibrutinib + Umbralisib NCT02874404 2 13 Completed R/R DLBCL ORR 31%
PFS 3 months		 [93]
BTK
PI3K
CD20		 Ibrutinib + Parsaclisib+ Rituximab+ Bendamustine NCT03424122 1 50 Active B-cell Lymphomas NA NA
BTK PI3K Ibrutinib + Umbralisib NCT02268851 1 45 Active CLL, SLL, MCL ORR 67%
CR 19%
PR 48%
AEs grade >3 in less than 10%		 [94]
BTK
PI3K
CD20		 Ibrutinib + Umbralisib + Ublituximab + Bendamustine NCT02006485 1 160 Completed B-cell Lymphomas DOR 20 months [95]
mTOR Everolimus + Lenalidomide NCT01075321 1 & 2 58 Completed MZL, FL, MCL, WM ORR 27% [96]
mTOR Everolimus + Panobinostat NCT00962507 1 11 Completed B-cell Lymphomas ORR 43%
CR 15%		 [97]
mTOR Everolimus + Panobinostat NCT00978432 2 50 Terminated DLBCL Terminated due to toxicities, which seemed to outweigh the benefits [98]
mTOR Everolimus + Panobinostat NCT00918333 1 & 2 124 Completed MZL, BL, MCL, SLL, CLL, ALL, WM NA NA
mTOR
CD20		 Everolimus + Rituximab NCT00869999 2 26 Completed DLBCL OR 38%
SD 8%
DOR 8.1 months		 [99]
mTOR Everolimus + Sorafenib NCT00474929 1 & 2 103 Completed B-cell Lymphomas ORR 30% in DLBCL and 38% in MCL
DOR 5.7 months		 [100]
mTOR Everolimus + Sotrastaurin NCT01854606 1 31 Completed ABC DLBCL Due to suboptimal tolerability of the combinations the phase II is not conducted NA
mTOR Sirolimus + hyperCVAD NCT01184885 Early 1 7 Completed ALL, BL, MCL NA NA NA
mTOR
CD22		 Temsirolimus + Inotuzumab oxogamicin NCT01535989 1 25 Completed R/R B-cell Lymphomas PR 39%
This drug combination is not possible due to toxicities		 [101]
PI3K
CD20		 Buparlisib + Rituximab NCT02049541 1 18 Active R/R FL, R/R MZL, R/R MCL, WM NA NA
PI3K
SYK		 Idelalisib + Entospletinib NCT01796470 2 66 Terminated B-cell Lymphomas Terminated due to pneumonitis in 18% of patients [102]
SYK TAK-659 + R-CHOP NCT03742258 1 12 Active DLBCL NA NA
Abbreviations: FL, follicular lymphoma; DLBCL, diffuse large B-cell lymphoma; MCL, mantle cell lymphoma; MZL, marginal zone lymphoma; NHL, non-Hodgkin lymphoma; CLL, chronic lymphocytic leukemia; MM, multiple myeloma; WM, waldenstrom’s macroglobulinemia; ORR, overall response rate; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; DOR, duration of response; PFS, progression-free survival; OS, overall survival; AEs, adverse effects; NA, not available.
Inhibitors of mTOR (mTORi) and SYK (SYKi) have also been evaluated in MCL and DLBCL. The mTORi temsirolimus was approved in 2009 in Europe for R/R MCL based on its efficacy in two phase 2 studies, showing ORR of 38-41% in monotherapy [50][51], later confirmed in phase 3 studies, with ORR between 22-47% [52][55]. Regarding SYKi, fostamatinib showed modest activity in monotherapy in both MCL and DLBCL in a phase 1/2 study, with ORR of 11% and 22%, respectively [77], and, more recently, TAK-659, a dual inhibitor of SYK and FMS-like tyrosine kinase 3 (FLT3), showed ORR of 28% in patients with R/R DLBCL [103]. Studies evaluating these and other inhibitors of mTOR and SYK, both in monotherapy and in combination, are summarized in Table 1 and Table 2.

3. Conclusions and Perspectives

With the development of genomic sequencing and immunotherapy, the treatment of aggressive B-cell lymphoma entered the era of precision therapy almost two decades ago. Targeting BCR signaling with oral kinase inhibitors has changed the treatment landscape in MCL. In this disease, the introduction of BTK inhibitors represents one of the most important advances in small molecule-based therapies, with high response rates and durable remissions in the relapse setting, and very encouraging results in the frontline setting. Conversely, despite the initial excitement and strong biological rationale, the latter has yet to demonstrate significant improvements in the outcome for DLBCL patients. As an example, single-agent ibrutinib is active and well tolerated in non-GCB DLBCL, but the duration of response is remarkably short in unselected patients, compared to MCL. In addition, in DLBCL, these approaches are often associated with significant toxicities in combination with chemo-immunotherapeutic regimens, such as R-CHOP, probably underlying the biological complexity and aggressiveness of this disease. Thus, durable responses in DLBCL patients will undoubtedly require combination therapies targeting genetically and experimentally validated biologic drivers. In this sense, “chemo-free” combination strategies associating ibrutinib with rituximab and lenalidomide in previously untreated non-GCB cases are showing prolonged responses with some complete responses, suggesting that these new regimens may have a role in frontline therapy. However, longer follow-ups will be required to confirm these promising results.
Besides DLBCL, these combinations may also improve the clinical outcomes of MCL patients, while ensuring manageable toxicity. The most recent trials are taking advantage of the safety profile of second-generation PI3Ki or BTKi, associating them either with secondary agents with a distinct mechanism of action, such as the BCL-2 antagonist venetoclax, the cyclin-dependent kinase (CDK)4/6 inhibitor (palbociclib), or together (ibrutinib + umbralisib or ibrutinib + copanlisib), in order to enhance the blockade of BCR signaling.
Finally, the use of CAR-T and immune checkpoint blockade therapies, such as programmed cell death protein 1 (PD1)/PD1 ligand (PD-L1) antagonists in combination with BTK (and probably PI3K) inhibitors may represent a significant step towards tailored medicine for the clinical management of both MCL and DLBCL.

This entry is adapted from the peer-reviewed paper 10.3390/cancers14040860

References

  1. Harris, C.M.; Foley, S.E.; Goedken, E.R.; Michalak, M.; Murdock, S.; Wilson, N.S. Merits and Pitfalls in the Characterization of Covalent Inhibitors of Bruton’s Tyrosine Kinase. SLAS Discov. 2018, 23, 1040–1050.
  2. Davis, R.E.; Ngo, V.N.; Lenz, G.; Tolar, P.; Young, R.M.; Romesser, P.B.; Kohlhammer, H.; Lamy, L.; Zhao, H.; Yang, Y.; et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 2010, 463, 88–92.
  3. Honigberg, L.A.; Smith, A.M.; Sirisawad, M.; Verner, E.; Loury, D.; Chang, B.; Li, S.; Pan, Z.; Thamm, D.H.; Miller, R.A.; et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc. Natl. Acad. Sci. USA 2010, 107, 13075–13080.
  4. Dasmahapatra, G.; Patel, H.; Dent, P.; Fisher, R.I.; Friedberg, J.; Grant, S. The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib. Br. J. Haematol. 2013, 161, 43–56.
  5. He, Y.; Li, J.; Ding, N.; Wang, X.; Deng, L.; Xie, Y.; Ying, Z.; Liu, W.; Ping, L.; Zhang, C.; et al. Combination of Enzastaurin and Ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma. J. Exp. Clin. Cancer Res. 2019, 38, 86.
  6. Yang, Y.; Shaffer, A.L.; Emre, N.C.T.; Ceribelli, M.; Zhang, M.; Wright, G.; Xiao, W.; Powell, J.; Platig, J.; Kohlhammer, H.; et al. Exploiting Synthetic Lethality for the Therapy of ABC Diffuse Large B Cell Lymphoma. Cancer Cell 2012, 21, 723–737.
  7. Barf, T.; Covey, T.; Izumi, R.; Van De Kar, B.; Gulrajani, M.; Van Lith, B.; Van Hoek, M.; De Zwart, E.; Mittag, D.; Demont, D.; et al. Acalabrutinib (ACP-196): A covalent Bruton tyrosine kinase inhibitor with a differentiated selectivity and in vivo potency profile. J. Pharmacol. Exp. Ther. 2017, 363, 240–252.
  8. Harrington, B.K.; Gardner, H.L.; Izumi, R.; Hamdy, A.; Rothbaum, W.; Coombes, K.R.; Covey, T.; Kaptein, A.; Gulrajani, M.; Van Lith, B.; et al. Preclinical evaluation of the novel BTK inhibitor acalabrutinib in canine models of B-cell non-hodgkin lymphoma. PLoS ONE 2016, 11, e0159607.
  9. Spriano, F.; Tarantelli, C.; Gaudio, E.; Gerlach, M.M.; Priebe, V.; Cascione, L.; Bernasconi, E.; Targa, A.; Mascia, M.; Dirnhofer, S.; et al. Single and combined BTK and PI3Kδ inhibition with acalabrutinib and ACP-319 in pre-clinical models of aggressive lymphomas. Br. J. Haematol. 2019, 187, 595–601.
  10. Tarantelli, C.; Zhang, L.; Curti, E.; Gaudio, E.; Spriano, F.; Priebe, V.; Cascione, L.; Arribas, A.J.; Zucca, E.; Rossi, D.; et al. The Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrated synergies with other anti-lymphoma targeted agents. Haematologica 2019, 104, e307–e309.
  11. Li, N.; Sun, Z.; Liu, Y.; Guo, M.; Zhang, Y.; Zhou, D.; Zhang, B.; Su, D.; Zhang, S.; Han, J.; et al. Abstract 2597: BGB-3111 is a novel and highly selective Bruton’s tyrosine kinase (BTK) inhibitor. Cancer Res. 2015, 75, 2597.
  12. Gaudio, E.; Tarantelli, C.; Zucca, E.; Rossi, D.; Stathis, A.; Bertoni, F. Abstract 4182: The two novel BTK-inhibitors M2951 and M7583 show in vivo anti-tumor activity in pre-clinical models of B cell lymphoma. Cancer Res. 2017, 77, 4182.
  13. Cerulli, R.A.; Dashnamoorthy, R.; Evens, A.M. The Bruton’s Tyrosine Kinase Inhibitor CC-292 in Diffuse Large B-Cell Lymphoma (DLBCL), T-Cell Lymphoma (TCL), and Hodgkin Lymphoma (HL): Induction of Cell Death and Examination of Rational Novel/Novel Therapeutic Combinations. Blood 2014, 124, 1772.
  14. Yasuhiro, T.; Yoshizawa, T.; Daub, H.; Weber, C.; Narita, M.; Kawabata, K. Abstract 2021: ONO-WG-307, a novel, potent and selective inhibitor of Bruton’s tyrosine kinase (Btk), results in sustained inhibition of the ERK, AKT and PKD signaling pathways. Cancer Res. 2012, 72, 2021.
  15. Kozaki, R.; Yoshizawa, T.; Tohda, S.; Yasuhiro, T.; Hotta, S.; Ariza, Y.; Ueda, Y.; Narita, M.; Kawabata, K. Development of a Bruton’s Tyrosine Kinase (Btk) Inhibitor, ONO-WG-307: Efficacy in ABC-DLBCL Xenograft Model—Potential Treatment for B-Cell Malignancies. Blood 2011, 118, 3731.
  16. Ribeiro, M.L.; Reyes-Garau, D.; Vinyoles, M.; Profitós Pelejà, N.; Santos, J.C.; Armengol, M.; Fernández-Serrano, M.; Sedó Mor, A.; Bech-Serra, J.J.; Blecua, P.; et al. Antitumor Activity of the Novel BTK Inhibitor TG-1701 Is Associated with Disruption of Ikaros Signaling in Patients with B-cell Non–Hodgkin Lymphoma. Clin. Cancer Res. 2021, 5, 13.
  17. Wu, H.; Wang, W.; Liu, F.; Weisberg, E.L.; Tian, B.; Chen, Y.; Li, B.; Wang, A.; Wang, B.; Zhao, Z.; et al. Discovery of a potent, covalent BTK inhibitor for B-cell lymphoma. ACS Chem. Biol. 2014, 9, 1086–1091.
  18. Woyach, J.A.; Furman, R.R.; Liu, T.-M.; Ozer, H.G.; Zapatka, M.; Ruppert, A.S.; Xue, L.; Li, D.H.-H.; Steggerda, S.M.; Versele, M.; et al. Resistance Mechanisms for the Bruton’s Tyrosine Kinase Inhibitor Ibrutinib. N. Engl. J. Med. 2014, 370, 2286–2294.
  19. Eathiraj, S.; Savage, R.; Yu, Y.; Schwartz, B.; Woyach, J.; Johnson, A.; Reiff, S.; Abbadessa, G. Targeting Ibrutinib-Resistant BTK-C481S Mutation with ARQ 531, a Reversible Non-Covalent Inhibitor of BTK. Clin. Lymphoma Myeloma Leuk. 2016, 16, S47–S48.
  20. Yu, Y.; Eathiraj, S.; Savage, R.E.; Abbadessa, G.; Reiff, S.D.; Woyach, J.A.; Johnson, A.J.; Schwartz, B. ARQ 531, a Reversible BTK Inhibitor, Demonstrates Potent Anti-Tumor Activity in ABC-DLBCL and GCB-DLBCL biobehavioral aspects of chronic lymphocytic leukemia View project small-molecule inhibitors View project ARQ 531, A Reversible BTK Inhibitor, Demonstr. EHA Congr. 2017, E1400.
  21. Uckun, F.; Dibirdik, I.; Sarkissian, A.; Qazi, S. In vitro and in vivo chemosensitizing activity of LFM-A13, a dual-function inhibitor of Bruton’s tyrosine kinase and polo-like kinases, against human leukemic B-cell precursors. Arzneimittel-Forschung/Drug Res. 2011, 61, 252–259.
  22. Lee, N.; Li, Y.; Yuan, C.; Liu, G.; Yue, C. Discovery of HBW-3-10: A potent, orally active, reversible Bruton’s tyrosine kinase (BTK) inhibitor with antitumor activity in mice. J. Clin. Oncol. 2021, 39, e15062.
  23. Crawford, J.J.; Zhang, H. Discovery and Development of Non-Covalent, Reversible Bruton’s Tyrosine Kinase Inhibitor Fenebrutinib (GDC-0853). ACS Symp. Ser. 2019, 1332, 239–266.
  24. Thieme, E.; Lam, V.; Bruss, N.; Xu, F.; Kurtz, S.E.; Tyner, J.W.; Danilov, A.; Liu, T. Pharmacologic Inhibition of B Cell-Receptor-Associated Kinases with CG-806 Induces Apoptosis and Metabolic Reprogramming in Aggressive Non-Hodgkin Lymphoma (NHL) Models. Blood 2020, 136, 29.
  25. Asami, T.; Kawahata, W.; Kashimoto, S.; Sawa, M. Abstract B152: CB1763, a highly selective, novel non-covalent BTK inhibitor, targeting ibrutinib-resistant BTK C481S mutant. Mol. Cancer Ther. 2018, 17, B152.
  26. Gomez, E.B.; Wu, W.; Stephens, J.R.; Rosendahl, M.S.; Brandhuber, B.J. In Vivo Pre-Clinical Evaluation of LOXO-305 Alone and in Combination with Venetoclax, Rituximab, R-CHOP or Obinutuzumab on Human Xenograft Lymphoma Tumor Models in Mice. Blood 2020, 136, 32–33.
  27. Brandhuber, B.; Gomez, E.; Smith, S.; Eary, T.; Spencer, S.; Rothenberg, S.M.; Andrews, S. LOXO-305, A Next Generation Reversible BTK Inhibitor, for Overcoming Acquired Resistance to Irreversible BTK Inhibitors. Clin. Lymphoma Myeloma Leuk. 2018, 18, S216.
  28. Sun, Y.; Ding, N.; Song, Y.; Yang, Z.; Liu, W.; Zhu, J.; Rao, Y. Degradation of Bruton’s tyrosine kinase mutants by PROTACs for potential treatment of ibrutinib-resistant non-Hodgkin lymphomas. Leukemia 2019, 33, 2105–2110.
  29. Zhao, Y.; Shu, Y.; Lin, J.; Chen, Z.; Xie, Q.; Bao, Y.; Lu, L.; Sun, N.; Wang, Y. Discovery of novel BTK PROTACs for B-Cell lymphomas. Eur. J. Med. Chem. 2021, 225, 113820.
  30. Tinworth, C.P.; Lithgow, H.; Dittus, L.; Bassi, Z.I.; Hughes, S.E.; Muelbaier, M.; Dai, H.; Smith, I.E.D.; Kerr, W.J.; Burley, G.A.; et al. PROTAC-Mediated Degradation of Bruton’s Tyrosine Kinase Is Inhibited by Covalent Binding. ACS Chem. Biol. 2019, 14, 342–347.
  31. Jaime-Figueroa, S.; Buhimschi, A.D.; Toure, M.; Hines, J.; Crews, C.M. Design, synthesis and biological evaluation of Proteolysis Targeting Chimeras (PROTACs) as a BTK degraders with improved pharmacokinetic properties. Bioorganic Med. Chem. Lett. 2020, 30, 126877.
  32. Zorba, A.; Nguyen, C.; Xu, Y.; Starr, J.; Borzilleri, K.; Smith, J.; Zhu, H.; Farley, K.A.; Ding, W.D.; Schiemer, J.; et al. Delineating the role of cooperativity in the design of potent PROTACs for BTK. Proc. Natl. Acad. Sci. USA 2018, 115, E7285–E7292.
  33. Chen, L.; Monti, S.; Juszczynski, P.; Daley, J.; Chen, W.; Witzig, T.E.; Habermann, T.M.; Kutok, J.L.; Shipp, M.A. SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. Blood 2008, 111, 2230–2237.
  34. Cheng, S.; Coffey, G.; Zhang, X.H.; Shaknovich, R.; Song, Z.; Lu, P.; Pandey, A.; Melnick, A.M.; Sinha, U.; Wang, Y.L. SYK inhibition and response prediction in diffuse large B-cell lymphoma. Blood 2011, 118, 6342–6352.
  35. Suljagic, M.; Longo, P.G.; Bennardo, S.; Perlas, E.; Leone, G.; Laurenti, L.; Efremov, D.G. The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the Eμ-TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling. Blood 2010, 116, 4894–4905.
  36. Young, R.M.; Hardy, I.R.; Clarke, R.L.; Lundy, N.; Pine, P.; Turner, B.C.; Potter, T.A.; Refaeli, Y. Mouse models of non-hodgkin lymphoma reveal Syk as an important therapeutic target. Blood 2009, 113, 2508–2516.
  37. Ma, J.; Xing, W.; Coffey, G.; Dresser, K.; Lu, K.; Guo, A.; Raca, G.; Pandey, A.; Conley, P.; Yu, H.; et al. Cerdulatinib, a novel dual SYK/JAK kinase inhibitor, has broad anti-tumor activity in both ABC and GCB types of diffuse large B cell lymphoma. Oncotarget 2015, 6, 43881–43896.
  38. Axelrod, M.J.; Fowles, P.; Silverman, J.; Clarke, A.; Tang, J.; Rousseau, E.; Webb, H.K.; Di Paolo, J. The Combination of Entospletinib and Vincristine Demonstrates Synergistic Activity in a Broad Panel of Hematological Cancer Cell Lines and Anti-Tumor Efficacy in a DLBCL Xenograft Model. Blood 2015, 126, 5123.
  39. Huck, J.; Brake, R.; Tirrell, S.; He, H.; Theisen, M.; Yu, J.; Zhang, M.; Balani, S.; Atienza, J.; Vincent, P.; et al. Antitumor activity of inhibiting SYK kinase with TAK-659, an investigational agent, in DLBCL models. J. Clin. Oncol. 2014, 32, 8580.
  40. Lam, B.; Arikawa, Y.; Cramlett, J.; Dong, Q.; de Jong, R.; Feher, V.; Grimshaw, C.E.; Farrell, P.J.; Hoffman, I.D.; Jennings, A.; et al. Discovery of TAK-659 an orally available investigational inhibitor of Spleen Tyrosine Kinase (SYK). Bioorganic Med. Chem. Lett. 2016, 26, 5947–5950.
  41. Barta, S.K.; Rasco, D.W.; Chen, A.I.; Elkins, S.; Wang, M.; Denis, L.J.; Toker, S.; Usansky, H.; Reddy, S.; Rao, N.S. Clinical activity, safety and tolerability of ASN002, a dual JAK/SYK inhibitor, in patients with non-Hodgkin lymphoma (NHL), myeolfibrosis (MF), chronic lymphocytic leukemia (CLL) and solid tumors. J. Clin. Oncol. 2018, 36, TPS7084.
  42. Younes, A.; Samad, N. Utility of mTOR Inhibition in Hematologic Malignancies. Oncologist 2011, 16, 730–741.
  43. Yazbeck, V.Y.; Buglio, D.; Georgakis, G.V.; Li, Y.; Iwado, E.; Romaguera, J.E.; Kondo, S.; Younes, A. Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma. Exp. Hematol. 2008, 36, 443–450.
  44. Haritunians, T.; Mori, A.; O’Kelly, J.; Luong, Q.T.; Giles, F.J.; Koeffler, H.P. Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma. Leukemia 2007, 21, 333–339.
  45. Mortensen, D.S.; Fultz, K.E.; Xu, S.; Xu, W.; Packard, G.; Khambatta, G.; Gamez, J.C.; Leisten, J.; Zhao, J.; Apuy, J.; et al. CC-223, a potent and selective inhibitor of mTOR kinase: In vitro and in vivo characterization. Mol. Cancer Ther. 2015, 14, 1295–1305.
  46. Ezell, S.A.; Mayo, M.; Bihani, T.; Tepsuporn, S.; Wang, S.; Passino, M.; Grosskurth, S.E.; Collins, M.; Parmentier, J.; Reimer, C.; et al. Synergistic induction of apoptosis by combination of BTK and dual mTORC1/2 inhibitors in diffuse large B cell lymphoma. Oncotarget 2014, 5, 4990–5001.
  47. Tarantelli, C.; Gaudio, E.; Arribas, A.J.; Kwee, I.; Hillmann, P.; Rinaldi, A.; Cascione, L.; Spriano, F.; Bernasconi, E.; Guidetti, F.; et al. PQR309 is a novel dual PI3K/mTOR inhibitor with preclinical antitumor activity in lymphomas as a single agent and in combination therapy. Clin. Cancer Res. 2018, 24, 120–129.
  48. Wang, M.L.; Rule, S.; Martin, P.; Goy, A.; Auer, R.; Kahl, B.S.; Jurczak, W.; Advani, R.H.; Romaguera, J.E.; Williams, M.E.; et al. Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma. N. Engl. J. Med. 2013, 369, 507–516.
  49. Fisher, R.I.; Bernstein, S.H.; Kahl, B.S.; Djulbegovic, B.; Robertson, M.J.; De Vos, S.; Epner, E.; Krishnan, A.; Leonard, J.P.; Lonial, S.; et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J. Clin. Oncol. 2006, 24, 4867–4874.
  50. Witzig, T.E.; Geyer, S.M.; Ghobrial, I.; Inwards, D.J.; Fonseca, R.; Kurtin, P.; Ansell, S.M.; Luyun, R.; Flynn, P.J.; Morton, R.F.; et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J. Clin. Oncol. 2005, 23, 5347–5356.
  51. Ansell, S.M.; Inwards, D.J.; Rowland, K.M.; Flynn, P.J.; Morton, R.F.; Moore, D.F.; Kaufmann, S.H.; Ghobrial, I.; Kurtin, P.J.; Maurer, M.; et al. Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: A phase 2 trial in the North Central Cancer Treatment Group. Cancer 2008, 113, 508–514.
  52. Hess, G.; Herbrecht, R.; Romaguera, J.; Verhoef, G.; Crump, M.; Gisselbrecht, C.; Laurell, A.; Offner, F.; Strahs, A.; Berkenblit, A.; et al. Phase III study to evaluate temsirolimus compared with investigator’s choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J. Clin. Oncol. 2009, 27, 3822–3829.
  53. Goy, A.; Sinha, R.; Williams, M.E.; Besisik, S.K.; Drach, J.; Ramchandren, R.; Zhang, L.; Cicero, S.; Fu, T.; Witzig, T.E. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: Phase II MCL-001 (EMERGE) study. J. Clin. Oncol. 2013, 31, 3688–3695.
  54. Trněný, M.; Lamy, T.; Walewski, J.; Belada, D.; Mayer, J.; Radford, J.; Jurczak, W.; Morschhauser, F.; Alexeeva, J.; Rule, S.; et al. Lenalidomide versus investigator’s choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): A phase 2, randomised, multicentre trial. Lancet Oncol. 2016, 17, 319–331.
  55. Dreyling, M.; Jurczak, W.; Jerkeman, M.; Silva, R.S.; Rusconi, C.; Trneny, M.; Offner, F.; Caballero, D.; Joao, C.; Witzens-Harig, M.; et al. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: An international, randomised, open-label, phase 3 study. Lancet 2016, 387, 770–778.
  56. Rule, S.; Dreyling, M.; Goy, A.; Hess, G.; Auer, R.; Kahl, B.; Cavazos, N.; Liu, B.; Yang, S.; Clow, F.; et al. Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: A pooled analysis from three open-label studies. Br. J. Haematol. 2017, 179, 430–438.
  57. Wang, M.; Rule, S.; Zinzani, P.L.; Goy, A.; Casasnovas, O.; Smith, S.D.; Damaj, G.; Doorduijn, J.; Lamy, T.; Morschhauser, F.; et al. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): A single-arm, multicentre, phase 2 trial. Lancet 2018, 391, 659–667.
  58. Song, Y.; Zhou, K.; Zou, D.; Zhou, J.; Hu, J.; Yang, H.; Zhang, H.; Ji, J.; Xu, W.; Jin, J.; et al. Treatment of Patients with Relapsed or Refractory Mantle–Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton’s Tyrosine Kinase. Clin. Cancer Res. 2020, 26, 4216–4224.
  59. Dyer, M.J.; De Vos, S.; Ruan, J.; Flowers, C.; Maddocks, K.J.; Rule, S.; Hamdy, A.M.; Izumi, R.; Slatter, J.G.; Cheung, J.; et al. Acalabrutinib monotherapy in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). J. Clin. Oncol. 2018, 36, 7547.
  60. Song, Y.; Schuster, S.J.; He, W.; Zhu, J.; Deng, L.; Sun, Y.; Ding, N.; Wang, X.; Gill, J.; Chatburn, E.T.; et al. Simultaneous Global Phase I Studies of a Differentiated BTK Inhibitor, Dtrmwxhs-12, in Relapsed/Refractory Patients with Chronic Lymphocytic Leukemia and B-Cell Lymphomas. Blood 2017, 130, 4056.
  61. Advani, R.H.; Buggy, J.J.; Sharman, J.P.; Smith, S.M.; Boyd, T.E.; Grant, B.; Kolibaba, K.S.; Furman, R.R.; Rodriguez, S.; Chang, B.Y.; et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J. Clin. Oncol. 2013, 31, 88–94.
  62. Tobinai, K.; Ogura, M.; Ishizawa, K.; Suzuki, T.; Munakata, W.; Uchida, T.; Aoki, T.; Morishita, T.; Ushijima, Y.; Takahara, S. Safety and tolerability of ibrutinib monotherapy in Japanese patients with relapsed/refractory B cell malignancies. Int. J. Hematol. 2016, 103, 86–94.
  63. Wilson, W.H.; Young, R.M.; Schmitz, R.; Yang, Y.; Pittaluga, S.; Wright, G.; Lih, C.J.; Williams, P.M.; Shaffer, A.L.; Gerecitano, J.; et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat. Med. 2015, 21, 922–926.
  64. Graf, S.A.; Cassaday, R.D.; Morris, K.K.; Behnia, S.; Wu, Q.V.; Voutsinas, J.M.; Lynch, R.C.; Krakow, E.; Rasmussen, H.A.; Chauncey, T.R.; et al. Ibrutinib in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma: Final Results from a Prospective Phase II Study. Blood 2019, 134, 1596.
  65. Rule, S.; Dreyling, M.H.; Goy, A.; Hess, G.; Auer, R.; Kahl, B.S.; Hernandez-Rivas, J.A.; Qi, K.; Deshpande, S.; Parisi, L.; et al. Long-Term Outcomes with Ibrutinib Versus the Prior Regimen: A Pooled Analysis in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) with up to 7.5 Years of Extended Follow-up. Blood 2019, 134, 1538.
  66. Yang, H.; Xiang, B.; Song, Y.; Zhang, H.; Zhao, W.; Zou, D.; Lv, F.; Bai, O.; Liu, A.; Li, C.; et al. Zanubrutinib monotherapy for patients with relapsed or refractory non-germinal center diffuse large B-cell lymphoma: Results from a phase II, single-arm, multicenter, study. J. Clin. Oncol. 2020, 38, e20051.
  67. Goy, A.; Ribrag, V.; Varga, A.; Witzig, T.E.; Ocio, E.M.; Paz-Ares, L.G.; Mita, M.M.; Meyer, T.; Munster, P.N.; Mahipal, A.; et al. Phase I expansion trial of an oral TORC1/TORC2 inhibitor (CC-223) in diffuse large B-cell lymphoma (DLBCL) and multiple myeloma (MM). J. Clin. Oncol. 2013, 31, 8522.
  68. Kater, A.P.; Tonino, S.H.; Spiering, M.; Chamuleau, M.E.D.; Liu, R.; Adewoye, A.H.; Gao, J.; Dreiling, L.; Xin, Y.; Doorduijn, J.K.; et al. Final results of a phase 1b study of the safety and efficacy of the PI3Kδ inhibitor acalisib (GS-9820) in relapsed/refractory lymphoid malignancies. Blood Cancer J. 2018, 8, 16.
  69. Lanasa, M.C.; Glenn, M.; Mato, A.R.; Allgood, S.D.; Wong, S.; Amore, B.; Means, G.; Stevens, E.; Yan, C.; Friberg, G.; et al. First-In-Human Study Of AMG 319, a Highly Selective, Small Molecule Inhibitor Of PI3Kδ, In Adult Patients With Relapsed Or Refractory Lymphoid Malignancies. Blood 2013, 122, 678.
  70. Younes, A.; Salles, G.; Martinelli, G.; Bociek, R.G.; Barrigon, D.C.; Barca, E.G.; Turgut, M.; Gerecitano, J.; Kong, O.; Pisal, C.B.; et al. Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma. Haematologica 2017, 102, 2104–2112.
  71. Berdeja, J.G.; Oki, Y.; Patel, M.R.; Copeland, A.; Flinn, I.; Neelapu, S.S.; Viner, J.; Wang, J.; Gerecitano, J.F.; Younes, A. Phase 1 first-in-human trial of oral CUDC-907, a dual inhibitor of PI3K and HDAC, in patients with refractory/relapsed lymphoma or multiple myeloma. J. Clin. Oncol. 2015, 33, 8537.
  72. Nastoupil, L.J.; Neelapu, S.S.; Davis, E.; Samaniego, F.; Fowler, N.H.; Westin, J.R.; Lee, H.J.; Wang, M.; Hagemeister, F.B.; Beer, P.; et al. Results of a First in Human, Dose Ascending, Phase I Study Examining the Safety and Tolerability of KA2237, an Oral PI3K p110β/δ Inhibitor in Patients with Relapsed/Refractory (R/R) B-Cell Lymphoma. Blood 2019, 134, 4099.
  73. Coleman, M.; Belada, D.; Casasnovas, R.O.; Gressin, R.; Lee, H.P.; Mehta, A.; Munoz, J.; Verhoef, G.; Corrado, C.; DeMarini, D.J.; et al. Phase 2 study of parsaclisib (INCB050465), a highly selective, next-generation PI3Kδ inhibitor, in relapsed or refractory diffuse large B-cell lymphoma (CITADEL-202). Leuk. Lymphoma 2021, 62, 368–376.
  74. Carlo-Stella, C.; Barde, P.; Delarue, R.; Scarfò, L.; Viswanadha, S.; Locatelli, S.; Gandolfi, S.; Pittari, V.; Morello, L.; Magagnoli, M.; et al. Safety and clinical activity of RP6530, a dual PI3Kδ/γ inhibitor, in patients with advanced hematologic malignancies: Final analysis of a phase 1 multi-center study. Hematol. Oncol. 2017, 35, 263.
  75. Burris, H.A.; Patel, M.R.; Lanasa, M.C.; Brander, D.; O’Connor, O.A.; Deng, C.; Gutierrez, M.; Jones, S.F.; Kuhn, J.G.; Miskin, H.P.; et al. Activity of TGR-1202, a novel once-daily PI3Kδ inhibitor, in patients with relapsed or refractory hematologic malignancies. J. Clin. Oncol. 2014, 32, 2513.
  76. Burris, H.A.; Flinn, I.; Lunning, M.A.; Vose, J.; Fowler, N.H.; Nastoupil, L.J.; O’Brien, S.M.; Schreeder, M.T.; Patel, M.R.; Fenske, T.; et al. Long-term follow-up of the PI3Kδ inhibitor TGR-1202 to demonstrate a differentiated safety profile and high response rates in CLL and NHL: Integrated-analysis of TGR-1202 monotherapy and combined with ublituximab. J. Clin. Oncol. 2016, 34, 7512.
  77. Friedberg, J.W.; Sharman, J.; Sweetenham, J.; Johnston, P.B.; Vose, J.M.; LaCasce, A.; Schaefer-Cutillo, J.; De Vos, S.; Sinha, R.; Leonard, J.P.; et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2010, 115, 2578–2585.
  78. Forero-Torres, A.; Ramchandren, R.; Yacoub, A.; Wertheim, M.S.; Edenfield, W.J.; Caimi, P.; Gutierrez, M.; Akard, L.; Escobar, C.; Call, J.; et al. Parsaclisib, a potent and highly selective PI3Kd inhibitor, in patients with relapsed or refractory B-cell malignancies. Blood 2019, 133, 1742–1752.
  79. Mehta, A.; Trněný, M.; Walewski, J.; Ribrag, V.; Dartigeas, C.; Christensen, J.H.; Pane, F.; Rodriguez, G.; Taszner, M.; Venugopal, P.; et al. Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Mantle Cell Lymphoma Not Previously Treated with a BTK Inhibitor: Primary Analysis from a Phase 2 Study (CITADEL-205). Blood 2021, 138, 382.
  80. Mehta, A.; Trněný, M.; Walewski, J.; Ribrag, V.; Dartigeas, C.; Christensen, J.H.; Pane, F.; Rodríguez, G.; Taszner, M.; Venugopal, P.; et al. Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Mantle Cell Lymphoma Not Previously Treated with a BTK Inhibitor (CITADEL-205). Blood 2020, 136, 22–23.
  81. Witzig, T.E.; Maddocks, K.J.; De Vos, S.; Lyons, R.M.; Edenfield, W.J.; Sharman, J.P.; Vose, J.; Yimer, H.A.; Wei, H.; Chan, E.M.; et al. Phase 1/2 trial of acalabrutinib plus pembrolizumab (Pem) in relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL). J. Clin. Oncol. 2019, 37, 7519.
  82. Younes, A.; Sehn, L.H.; Johnson, P.; Zinzani, P.L.; Hong, X.; Zhu, J.; Patti, C.; Belada, D.; Samoilova, O.; Suh, C.; et al. Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non–germinal center B-cell diffuse large B-cell lymphoma. J. Clin. Oncol. 2019, 37, 1285–1295.
  83. Sauter, C.S.; Matasar, M.J.; Schoder, H.; Devlin, S.M.; Drullinsky, P.; Gerecitano, J.; Kumar, A.; Noy, A.; Palomba, M.L.; Portlock, C.S.; et al. A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL. Blood 2018, 131, 1805–1808.
  84. Gauthier, J.; Hirayama, A.V.; Purushe, J.; Hay, K.A.; Lymp, J.; Li, D.H.; Yeung, C.C.S.; Sheih, A.; Pender, B.S.; Hawkins, R.M.; et al. Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure. Blood 2020, 135, 1650–1660.
  85. Bonnet, C.M.; Lamy, T.; Fruchart, C.; Le Gouill, S.; Gunzer, K.; Gastinne, T.; Jardin, F.; Karlin, L.; Houot, R.; Dupuis, J.; et al. Ibrutinib in association with R-DHAP/ox for patients with relapsed/refractory b-cell lymphoma: Results of the escalating phase of the BIBLOS phase Ib LYSA study. J. Clin. Oncol. 2018, 36, e19550.
  86. Beatty, G.L.; Shahda, S.; Beck, T.; Uppal, N.; Cohen, S.J.; Donehower, R.; Gabayan, A.E.; Assad, A.; Switzky, J.; Zhen, H.; et al. A Phase Ib/II Study of the JAK1 Inhibitor, Itacitinib, plus nab -Paclitaxel and Gemcitabine in Advanced Solid Tumors. Oncologist 2019, 24, 14.
  87. Fowler, N.H.; Nastoupil, L.; De Vos, S.; Knapp, M.; Flinn, I.W.; Chen, R.; Advani, R.H.; Bhatia, S.; Martin, P.; Mena, R.; et al. The combination of ibrutinib and rituximab demonstrates activity in first-line follicular lymphoma. Br. J. Haematol. 2020, 189, 650–660.
  88. Maddocks, K.; Christian, B.; Jaglowski, S.; Flynn, J.; Jones, J.A.; Porcu, P.; Wei, L.; Jenkins, C.; Lozanski, G.; Byrd, J.C.; et al. A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma. Blood 2015, 125, 242–248.
  89. Westin, J.R.; Nastoupil, L.J.; Fayad, L.; Hagemeister, F.B.; Oki, Y.; Turturro, F.; Ahmed, S.; Rodriguez, M.A.; Lee, H.J.; Steiner, R.E.; et al. Smart Start: Rituximab, Lenalidomide, and Ibrutinib Alone and in Combination with Standard Chemotherapy for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: Final Phase II Results. Blood 2019, 134, 1581.
  90. Ramchandren, R.; Johnson, P.; Ghosh, N.; Ruan, J.; Ardeshna, K.M.; Johnson, R.; Verhoef, G.; Cunningham, D.; de Vos, S.; Kassam, S.; et al. Phase 2 Results of the iR2 Regimen (Ibrutinib, Lenalidomide, and Rituximab) in Patients with Relapsed/Refractory (R/R) Non-Germinal Center B Cell-like (Non-GCB) Diffuse Large B-Cell Lymphoma (DLBCL). Blood 2019, 134, 761.
  91. Brown, J.R.; Harb, W.A.; Hill, B.T.; Gabrilove, J.; Sharman, J.P.; Schreeder, M.T.; Barr, P.M.; Foran, J.M.; Miller, T.P.; Burger, J.A.; et al. Phase I study of single-agent CC-292, a highly selective bruton’s tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia. Haematologica 2016, 101, e295–e298.
  92. Zhang, Q.; Tao, R.; Li, Z.; Guo, H.; Ji, M.; Zhang, L.; Huang, J.; Zhong, J.; Zhou, J. Zanubrutinib (BGB-3111) in combination with rituximab in patients with relapsed/refractory nonhodgkin lymphoma. HemaSphere 2020, 4, 596.
  93. Dhillon, S.; Keam, S.J. Umbralisib: First Approval. Drugs 2021, 81, 857–866.
  94. Davids, M.S.; Kim, H.T.; Nicotra, A.; Savell, A.; Francoeur, K.; Hellman, J.M.; Bazemore, J.; Miskin, H.P.; Sportelli, P.; Stampleman, L.; et al. Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: A multicentre phase 1–1b study. Lancet Haematol. 2019, 6, e38–e47.
  95. Lunning, M.; Vose, J.; Nastoupil, L.; Fowler, N.; Burger, J.A.; Wierda, W.G.; Schreeder, M.T.; Siddiqi, T.; Flowers, C.R.; Cohen, J.B.; et al. Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2019, 134, 1811–1820.
  96. Padrnos, L.; Ernst, B.; Dueck, A.C.; Kosiorek, H.E.; Ginos, B.F.; Toro, A.; Johnston, P.B.; Habermann, T.M.; Leis, J.F.; Mikhael, J.R.; et al. A Novel Combination of the mTORC1 Inhibitor Everolimus and the Immunomodulatory Drug Lenalidomide Produces Durable Responses in Patients With Heavily Pretreated Relapsed Lymphoma. Clin. Lymphoma Myeloma Leuk. 2018, 18, 664–672.e2.
  97. Oki, Y.; Buglio, D.; Fanale, M.; Fayad, L.; Copeland, A.; Romaguera, J.; Kwak, L.W.; Pro, B.; De Castro Faria, S.; Neelapu, S.; et al. Phase i study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma. Clin. Cancer Res. 2013, 19, 6882–6890.
  98. Islam, P.; Rizzieri, D.; Lin, C.; de Castro, C.; Diehl, L.; Li, Z.; Moore, J.; Morris, T.; Beaven, A. Phase II Study of Single-Agent and Combination Everolimus and Panobinostat in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Cancer Investig. 2021, 39, 871–879.
  99. Barnes, J.A.; Jacobsen, E.; Feng, Y.; Freedman, A.; Hochberg, E.P.; LaCasce, A.S.; Armand, P.; Joyce, R.; Sohani, A.R.; Rodig, S.J.; et al. Everolimus in combination with rituximab induces complete responses in heavily pretreated diffuse large B-cell lymphoma. Haematologica 2013, 98, 615–619.
  100. Witzig, T.E.; Reeder, C.B.; Laplant, B.R.; Gupta, M.; Johnston, P.B.; Micallef, I.N.; Porrata, L.F.; Ansell, S.M.; Colgan, J.P.; Jacobsen, E.D.; et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia 2011, 25, 341–347.
  101. Pirosa, M.C.; Zhang, L.; Hitz, F.; Novak, U.; Hess, D.; Terrot, T.; Pascale, M.; Mazzucchelli, L.; Bertoni, F.; Cavalli, F.; et al. A phase I trial of inotuzumab ozogamicin in combination with temsirolimus in patients with relapsed or refractory CD22-positive B-cell non-Hodgkin lymphomas. Leuk. Lymphoma 2021, 63, 117–123.
  102. Barr, P.M.; Saylors, G.B.; Spurgeon, S.E.; Cheson, B.D.; Greenwald, D.R.; O’Brien, S.M.; Liem, A.K.D.; Mclntyre, R.E.; Joshi, A.; Abella-Dominicis, E.; et al. Phase 2 study of idelalisib and entospletinib: Pneumonitis limits combination therapy in relapsed refractory CLL and NHL. Blood 2016, 127, 2411–2415.
  103. Gordon, L.I.; Kaplan, J.B.; Popat, R.; Burris, H.A.; Ferrari, S.; Madan, S.; Patel, M.R.; Gritti, G.; El-Sharkawi, D.; Chau, I.; et al. Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-Cell Lymphoma A C. Clin. Cancer Res. 2020, 26, 3546–3556.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
This entry is offline, you can click here to edit this entry!
ScholarVision Creations
Feedback